These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 1220958)

  • 1. [Pilot study on the effects of an antiparkinson anticholinergic agent during depressive conditions].
    Gisselmann A; Marin A; Simon P
    Encephale; 1975; 1(4):363-6. PubMed ID: 1220958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical study of the therapeutic effects of tofenacine in depressive states. Pilot study of 100 cases].
    Brasseur R
    Encephale; 1971; 60(3):265-79. PubMed ID: 5119349
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety.
    Gerlach J; Rasmussen PT; Hansen L; Kristjansen P
    Acta Psychiatr Scand; 1977 Apr; 55(4):251-60. PubMed ID: 324238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of improvement in depressive symptoms with fluoxetine treatment.
    Worthington J; Fava M; Davidson K; Alpert J; Nierenberg AA; Rosenbaum JF
    Psychopharmacol Bull; 1995; 31(2):223-6. PubMed ID: 7491372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant effect of transdermal nicotine patches in nonsmoking patients with major depression.
    Salín-Pascual RJ; Rosas M; Jimenez-Genchi A; Rivera-Meza BL; Delgado-Parra V
    J Clin Psychiatry; 1996 Sep; 57(9):387-9. PubMed ID: 9746444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with haloperidol and orphenadrine in schizophrenia. A clinical and pharmacokinetic study.
    Altamura AC; Buccio M; Colombo G; Terzi A; Cazzullo CL
    Encephale; 1986; 12(1):31-6. PubMed ID: 3698889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Depressive symptomatology and sleep apnea syndrome].
    Pochat MD; Ferber C; Lemoine P
    Encephale; 1993; 19(6):601-7. PubMed ID: 12404778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The use of synthetic antiparkinson agents as antidepressive agents].
    Wirth JF
    Ann Med Psychol (Paris); 1979; 137(3-4):245-50. PubMed ID: 496148
    [No Abstract]   [Full Text] [Related]  

  • 9. Anticholinergic drug-induced delirium in an elderly Alzheimer's dementia patient.
    Gareri P; De Fazio P; Cotroneo A; Lacava R; Gallelli L; De Fazio S; De Sarro G
    Arch Gerontol Geriatr; 2007; 44 Suppl 1():199-206. PubMed ID: 17317453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing and managing antidepressant side effects.
    McElroy SL; Keck PE; Friedman LM
    J Clin Psychiatry; 1995; 56 Suppl 2():49-55. PubMed ID: 7844107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.
    Jacobsen FM
    J Clin Psychiatry; 1990 Jul; 51(7):298-302. PubMed ID: 2365668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression.
    Dominguez RA; Goldstein BJ; Jacobson AF; Steinbook RM
    J Clin Psychiatry; 1985 Mar; 46(3):84-7. PubMed ID: 3918993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Night locomotor activity and quality of sleep in quetiapine-treated patients with depression.
    Todder D; Caliskan S; Baune BT
    J Clin Psychopharmacol; 2006 Dec; 26(6):638-42. PubMed ID: 17110822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical pharmacology of anticholinergic antiparkinson agents. A review with emphasis on acute toxicity].
    Gjerden P; Slørdal L
    Tidsskr Nor Laegeforen; 1998 Jan; 118(1):53-5. PubMed ID: 9481912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal of orphenadrine.
    Gjerden P; Slørdal L; Bramness JG
    Br J Clin Pharmacol; 2009 Aug; 68(2):238-42. PubMed ID: 19694744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [An original psychotropic drug: sulpiride].
    Borenstein P; Champion C; Cujo P; Gekière F; Olivenstein C; Kramarz P
    Sem Hop; 1969 Apr; 45(19):1301-14. PubMed ID: 4307000
    [No Abstract]   [Full Text] [Related]  

  • 18. [Results of efficacy study with diclofenac/orphenadrine infusions in patients with musculoskeletal diseases and functional disorders].
    Aglas F; Fruhwald FM; Chlud K
    Acta Med Austriaca; 1998; 25(3):86-90. PubMed ID: 9816400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Fatalities caused by anticholinergic antiparkinsonian drugs. Analysis of findings in a 11-year national material].
    Gjerden P; Engelstad KS; Pettersen G; Slørdal L
    Tidsskr Nor Laegeforen; 1998 Jan; 118(1):42-4. PubMed ID: 9481909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CL-67,772: a preliminary evaluation of a potential antidepressant compound. Animal and human correlations.
    Gallant DM; Bishop MP; Guerrero-Figueroa R
    Curr Ther Res Clin Exp; 1971 Jun; 13(6):364-8. PubMed ID: 4996222
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.